SCHEMBL6344008

SCHEMBL6344008

CC(C)S(=O)(=O)NC1CCCCC1(O)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 5/20 0.40
SLC6A3 Q01959 2/20 0.40
ESR1 P03372 1/20 0.40
PGR P06401 1/20 0.40
HTR2A P28223 1/20 0.40
TRPC5 Q9UL62 1/20 0.40
GRIA4 P48058 5/20 0.39
SLC6A9 P48067 7/20 0.38
OPRM1 P35372 3/20 0.37
OPRL1 P41146 2/20 0.37
SLC6A5 Q9Y345 2/20 0.37
SLC6A4 P31645 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345740 0.96 GRIA4 (0.40) TRPA1SLC6A3ESR1PGRHTR2A
SCHEMBL6348747 0.89 GRIA4 (0.36) ESR1GRIA4OPRM1SLC6A4
SCHEMBL6353145 0.87 GRIA4 (0.45) TRPA1GRIA4SLC6A9OPRM1OPRL1
SCHEMBL6353143 0.87 GRIA4 (0.45) TRPA1GRIA4SLC6A9OPRM1OPRL1
SCHEMBL6345849 0.85 GRIA4 (0.41) SLC6A3GRIA4SLC6A4KCNH2
SCHEMBL6357784 0.85 SLC6A4 (0.43) SLC6A3SLC6A9OPRM1OPRL1SLC6A5
SCHEMBL6244911 0.85 SLC6A4 (0.43) SLC6A3SLC6A9OPRM1OPRL1SLC6A5
SCHEMBL6345852 0.85 GRIA4 (0.41) SLC6A3GRIA4SLC6A4KCNH2
SCHEMBL6357523 0.85 GRIA4 (0.41) SLC6A3GRIA4SLC6A4KCNH2
SCHEMBL6345585 0.85 SLC6A4 (0.43) SLC6A3SLC6A9OPRM1OPRL1SLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP disclosed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 TRPA1 355/4885SLC6A3 73/4885ESR1 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.